by Richard Daverman, PhD
December 18, 2012 -- WuXi PharmaTech, a CRO known mostly for its pre-clinical services is forming a JV with PRA, a US-based clinical-stage CRO. The JV will offer Phase I-IV clinical trial management and related services in China, Hong Kong and Macau. WuXi entered the clinical sphere in a small way one year ago by buying MedKey Med-Tech Development, a CRO located in China. But the company seems to have wanted a bigger presence on the clinical side, a presence that would be closer to its eminent stature in the pre-clinical market More details....
Stock Symbol: (NYSE: WX)
